Good MorningResilient equity markets were able to advance in the prior week. The S&P 500 gained more than 1% to trade just shy of record highs. The move came in the face of hot inflation and weak retail sales data, revealing a market focused on earnings and capital returns, which are expected to grow robustly this year.
Next week's hurdles center around the FOMC minutes. The minutes will likely reveal a hawkish Fed and affirm the diminished expectations for interest rate reduction this year. Featured: Is this Elon’s true agenda? (Altimetry) 
|
Stocks | | |
Chevron Corp. (NYSE: CVX) announced it was laying off approximately 20% of its global workforce by the end of 2026. The company announced the moves as an effort to cut costs, simplify its business, and complete its ongoing merger with Hess Corp. (NYSE: HES).
After falling about 2% on the announce... Read the Full Story |
|
From Our PartnersIt's a groundbreaking opportunity that could be poised for extraordinary gains.
The catalyst behind this surge is a massive new blockchain development… | | | | YES, I WANT THE #1 CRYPTO NOW |
|
Markets | | | Global shares traded mixed on Monday as investors continued to watch economic data and policy moves from U.S. President Donald Trump, as both are likely to impact upcoming central bank moves.France's CAC 40 dipped nearly 0.1% in early trading to 8,171.59, while Germany's DAX added 0.4% to 22,560.00.... Read the Full Story |
|
Markets | | |
If you're seeking growth in 2025, technology stocks and the semiconductor sector remain key areas to watch. Semiconductors are the foundation of the ongoing artificial intelligence (AI) revolution, which is still in its early stages. The recent rise of DeepSeek further strengthens the case for fut... Read the Full Story |
|
From Our PartnersThis isn't just another investment.
It might be the last retirement stock you'll ever need.
But this window of opportunity is closing fast. | | | | Click here for the ticker >>> |
|
Tech | | | Germany hasn't seen significant economic growth in five years. It's a stunning turnaround for Europe's biggest economy, which for much of this century had expanded exports and dominated world trade in engineered products like industrial machinery and luxury cars. So what happened? Here are five reas... Read the Full Story |
|
Tech | | | Germany hasn't seen significant economic growth in five years. It's a stunning turnaround for Europe's biggest economy, which for much of this century had expanded exports and dominated world trade in engineered products like industrial machinery and luxury cars. So what happened? Here are five reas... Read the Full Story |
|
|
Markets | | | Germany needs a new business model. The old one, fueled by cheap natural gas from Russia and lucrative exports to China, is broken, leaving Europe's biggest economy mired in stagnation and angst about the future. Delivering that fresh growth strategy is going to be the biggest challenge for the gove... Read the Full Story |
|
Markets | | | China's President Xi Jinping met with private sector business leaders on Monday, offering them assurances that policies regarding the private sector would not change, state media reported, as government officials work to revive an economy disrupted by a pandemic, regulatory crackdowns and a real est... Read the Full Story |
|
Markets | | |
Roblox (NYSE: RBLX), one of the hotter stocks in the gaming industry over the past 52 weeks, just had much of its 2025 gains wiped out. Prior to the company’s latest earnings report, shares were up over 30% on the year. As of the Feb. 13 close, markets have pared those gains down to just 1... Read the Full Story |
|
Markets | | |
Discount retailers have become an attractive investment opportunity due to the current economic climate of persistent inflation. As consumers face rising costs for goods and services, the appeal of discount retailers, who offer consistently lower prices than traditional retail sector outlets, grow... Read the Full Story |
|
Markets | | |
Markets have hit shares of robotic warehouse systems company Symbotic (NASDAQ: SYM) hard over the past 52 weeks. Shares of the industrials stock have lost nearly 37% of their value as of the Feb. 13 close. Retail giant Walmart (NYSE: WMT) is a huge Symbotic customer, a testament to the company&rsq... Read the Full Story |
|
Monday's Early Bird Stock Of The Day BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada. | Should I Buy BriaCell Therapeutics Stock? BCTX Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of BriaCell Therapeutics was last updated on Monday, February 17, 2025 at 1:05 AM.
BriaCell Therapeutics Bull Case -
BriaCell Therapeutics Corp. recently closed a public offering, raising $3.05 million, which can provide the necessary capital for further development of its immunotherapy products.
-
The company is advancing its lead candidate, Bria-IMT, in a pivotal Phase 3 study for metastatic breast cancer, indicating strong potential for market entry and revenue generation.
-
Bria-OTS, a personalized off-the-shelf immunotherapy platform, is currently in Phase 1/2 studies, which could lead to innovative treatment options and broaden the company's market reach.
-
The current stock price is $4.00 per share, which may present an attractive entry point for investors looking to capitalize on the company's growth potential.
-
BriaCell Therapeutics Corp. operates in the pharmaceutical preparations industry, which is known for its potential high returns, especially in the immuno-oncology sector.
BriaCell Therapeutics Bear Case -
The company is still in the clinical stage, meaning it has not yet generated revenue from its products, which can pose a risk for investors seeking immediate returns.
-
BriaCell Therapeutics Corp. relies heavily on the success of its clinical trials; any setbacks or failures could significantly impact its stock price and investor confidence.
-
As a small-cap biotechnology firm, BriaCell may face challenges in securing additional funding or partnerships, which could hinder its growth and development plans.
-
The competitive landscape in the immuno-oncology field is intense, with many established players, which could limit BriaCell's market share and profitability.
-
Market volatility and investor sentiment towards biotech stocks can lead to unpredictable stock price movements, adding an element of risk for potential investors.
| | View Today's Stock Pick |
|
